According to the World Health Organization, 285 million people around the world are visually impaired, and 90% of visual impairment results from chronic eye diseases like glaucoma, age-related macular degeneration, corneal opacities/cataracts, and diabetic retinopathy (http://www.who.int/blindness). Optic neuritis is one of the most common causes of visual impairment resulting from a neurological disorder. 1 In this issue, Soelberg et al. 2 reported the epidemiology of optic neuritis in Denmark, showing the overall agespecific incidence of optic neuritis to be 3.28 per 100,000 person-years in Denmark. Such figures double the age-specific incidence of 1.40 per 100,000 person-years found in Sweden 25 years ago, 3 reflecting the increased frequency observed in recent studies at tertiary centers. 4 An update of the epidemiology of this condition is timely given its significant clinical implication. Furthermore, the increased prevalence highlights that improving optic neuritis care should be given higher priority, both stimulating drug development programs and offering timely therapeutic interventions to patients in order to prevent permanent disability.
Optic neuritis is frequently observed in conjunction with multiple sclerosis (MS) relapses, although it is also part of the neuromyelitis optica spectrum disorders (NMOSD) and it is associated with the presence of anti-aquaporin 4 (AQP4) or anti-myelin oligodendrocyte glycoprotein (MOG) antibodies. 1 Disease diagnosis has evolved with the appearance of new diagnostic criteria for MS 5 and neuromyelitis optica (NMO), 6 the former allowing early diagnosis via imaging based on the spatiotemporal dissemination of lesions. As such, 40% of the cases in Soelberg's study were diagnosed with MS at presentation or after a short follow-up. Early diagnosis of MS was clearly supported by the spatiotemporal magnetic resonance imaging (MRI) evidence of lesions and by the presence of oligoclonal bands in the cerebrospinal fluid, highlighting the need to perform such tests at presentation in ophthalmology practices, or through referral to neurology services. Moreover, antibody testing identified 4% of cases with anti-MOG-mediated optic neuritis, although in none of these were anti-AQP4 antibodies detected. Therefore, advances in the diagnosis of demyelinating diseases have had an important impact on the identification of patients with optic neuritis at risk of suffering chronic and disabling diseases like MS and NMO.
Currently, the most important challenge is to diagnose all cases of optic neuritis as early as possible in order to offer them the best therapeutic approach and prevent future disability due to MS or NMOSD. With the availability of many effective disease-modifying drugs, it is critical that all cases are properly diagnosed at referral centers to control the underlying disorders. Moreover, significant efforts are underway to develop neuroprotective and remyelinating therapies that may prevent any long-term disability, 7,8 many of them using optic neuritis as their initial indication to test efficacy given the eloquence of the visual pathway. 9, 10 For this reason, optic neuritis can be now considered an emergency condition, in a similar way as the stroke code has been developed, and under the assumption that time is brain. 11 Recent studies using optical coherence tomography show that the degree of retinal damage in optic neuritis is highly predictive of visual impairment and the quality of vision 12 and that such damage is produced in the first days after onset. 13 Therefore, management of optic neuritis should be updated in the years to come under the notion that time is vision.
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